Therapy for coeliac disease (CD) mainly relies on following a gluten-free diet (GFD); however, a serum marker for gluten intake has yet to be established.
SUMMARY Background
Therapy for coeliac disease (CD) mainly relies on following a gluten-free diet (GFD); however, a serum marker for gluten intake has yet to be established.
Aim
To evaluate the utility of alkylresorcinol concentrations for detecting gluten intake in studies of human and mouse.
Methods
Alkylresorcinol concentrations were compared among treated patients with coeliac disease (n = 34), untreated coeliac disease patients (n = 36) and controls (n = 33). Furthermore, seven additional coeliac disease patients whose serum samples were available at diagnosis and after GFD were evaluated. In mice studies, alkylresorcinol concentrations were compared in the serum of five mice fed a regular chow and 10 mice fed lifelong with a gluten-free chow. In addition, the effect of adding gluten on changes of alkylresorcinol concentrations was also evaluated.
Results
Total alkylresorcinol concentrations were significantly lower in treated with coeliac disease [median (IQR), 3 (2-8) nmol/L], compared to untreated patients [median (IQR), 32 nmol/L; P < 0.0001] or healthy controls [median (IQR), 54 (23-112) nmol/L; P < 0.0001]. Moreover, alkylresorcinol concentrations in coeliac disease patients significantly decreased after introduction of a GFD (median, 34 nmol/L at diagnosis vs. 5 nmol/L after GFD, P = 0.02). In the mice, median (IQR) total alkylresorcinol concentrations in serum samples of mice fed lifelong with a gluten-free chow was 1.8 (1.6-2.3) nmol/L, which was further significantly increased to 16 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) nmol/L after 8 days of feeding with the gluten-free chow that had gluten added to it. (P = 0.008).
Conclusion
Serum alkylresorcinol concentrations could be a useful marker for dietary gluten in coeliac disease.
INTRODUCTION
Coeliac disease (CD) is a chronic inflammatory immune gastrointestinal disorder triggered by exposure to gluten in genetically predisposed individuals. 1 Gluten is a storage protein in wheat, barley and rye cereals that are widely used in the food and beverage sector. 2 The only effective therapy for CD is to follow a gluten-free diet (GFD); however, a strict GFD is not easy for patients to adhere to. This is because gluten is present in many types of food products, including wheat products, soy sauce and vegetarian meat substitutes, thereby limiting the efficacy of a GFD. 1, [3] [4] [5] Patients with CD are frequently and often unwittingly exposed to gluten-containing foods or products. 1, 3-7 Since Sulkanen et al. 8 first
showed the increase in tissue transglutaminase antibodies after a gluten challenge, there has been an unfulfilled need for a good biomarker for gluten intake.
9-11
Recently, the faecal or urine samples were used to determine the gluten ingestion and monitor GFD compliance in patients with CD; however, some limitations including difficulties in obtaining samples and inter-individual variability have been identified. 12, 13 A blood biomarker for gluten exposure/intake would be of benefit to CD patients and CD research to check for adherence to a GFD; however, a marker in blood for gluten intake has yet to be established. 5-n-Alkylresorcinols are long-chain phenolic lipids present in the outer layers of wheat, rye and barley grains.
14 They are present as five main odd-numbered alkyl-chain homologues ranging from 17 to 25 carbons long, with the distribution of the homologues specifically reflecting the type of cereal. Alkylresorcinols can be measured in serum, and the homologue fingerprint is reflected in serum, making it possible to distinguish between people who eat mainly wheat or rye. 15, 16 As alkylresorcinols are present in the outer layers of these grains, they are used as biomarkers of whole grain intake in epidemiological and intervention studies. 14, [17] [18] [19] [20] Small amounts of alkylresorcinols are found in the refined flour of wheat, 21 and the plasma of people who eat only refined wheat still contains measurable amounts of alkylresorcinols. 22 Because alkylresorcinols are mostly present in gluten-containing grains and show a unique fingerprint of each grain, alkylresorcinols could be markers of gluten intake in individuals on a GFD. 14, 23 A biomarker of gluten intake has great potential for improving understanding of the effectiveness of GFDs in preventing the symptoms of CD and in ensuring adherence to GFDs during testing of other therapies for CD.
To determine whether AR could function as a biomarker of gluten exposure, we measured serum concentrations of alkylresorcinols in patients with treated CD, patients with untreated CD, and healthy controls and in mice fed either gluten-containing chow or a chow free of both wheat and gluten
METHODS
Human study design A case-control study was conducted to evaluate the association between total AR concentrations and CD status. Serum samples of 70 patients with CD, which composed of 36 newly diagnosed patients and 34 treated CD patients, were obtained from an ongoing Celiac Disease Registry study at Mayo Clinic, which is prospectively recruiting CD patients who were referred to the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, Minnesota. In addition, corresponding controls who do not have CD were identified from a previous population-based study [24] [25] [26] after matching with newly diagnosed CD cases for age (AE5 years) and sex. Furthermore, seven additional CD patients whose sera were collected at diagnosis and after treatment were also evaluated to study the association between total AR concentrations and treatment with a GFD. The study was approved by the Institutional Review Board of Mayo Clinic. All cases of CD were diagnosed by positive tests for endomysial or tissue transglutaminase (tTG) antibodies and subsequent histological confirmation of the presence of intestinal villous atrophy. Serum samples of patients with untreated CD were collected at the start of or just before starting a GFD. Assessment for the adherence of gluten-free diet in patients with treated CD were evaluated by either a physician or dietician, and all treated CD patients were on the strict gluten-free diet. The sera samples from treated CD patients were obtained at least 6 months after the patients had been on a GFD. In this study, 2 tissue transglutaminase (tTG) immunoglobulin (Ig) A enzyme-linked immunosorbent assays were used. The reference values of the first tTG-IgA [Inova Diagnostics (San Diego, CA, USA), between 2000 and 2008] were: positive, equal or greater than 20 U/mL; negative, less than 20 U/mL. [27] [28] [29] The reference values of the second tTGIgA (Inova Diagnostics, after 2009) were: positive, equal or greater than 4 U/mL; negative, less than 4 U/ mL. 25, 26 Murine study design We further investigated the effect of gluten in mice that had been weaned and maintained on a wheat and GFD on total alkylresorcinols concentrations to determine if the AR assay was sensitive to gluten only and did not require the whole wheat grain flour. Transgenic mice that express HLA-DQ8 on an endogenous major histocompatibility complex class II-deficient background (NOD AB°DQ8) were used for this study. 30 Mice were weaned and maintained on a gluten-free chow in a conventional animal facility. 4-to 16-week-old mice were used, and all mouse studies performed were approved by the Institutional Animal Care and Use Committee of Mayo Clinic.
To compare the AR concentrations in serum between mice fed regular (gluten and whole wheat-containing) chow and mice fed wheat/gluten-free chow, one group (n = 5) was weaned on a regular mouse chow (glutencontaining) (LabDiet; PMI Nutrition International, St. Louis, MO, USA), and their parents had also consumed the same gluten-containing chow. The other group of NOD AB°DQ8 mice (n = 10) were weaned and maintained on a gluten-free chow, 30 and their parents were also maintained on the same gluten-free chow. Furthermore, we investigated whether the introduction of dietary vital gluten, which was isolated from refined wheat flour by solubilising the starch in water and leaving sticky insoluble gluten, influenced AR concentrations in mice fed lifelong with gluten-free chow. In this experiment, eight mice that were weaned and maintained on a gluten-free chow were switched to a gluten-free chow that had vital gluten added to it (Manildra Group, Shawnee Mission, KS, USA). For this custom-made chow (Dyets Inc., Bethlehem, PA, USA), 5% of the diet was vital gluten and the remaining components the same as the gluten-free chow. 31 Serum AR concentrations were measured before and after 8 days of feeding with the chow supplemented with 5% vital gluten. In addition, AR concentrations in mice chows were measured, including the regular chow, gluten-free chow and vital gluten added custom chow.
AR measurements
Serum AR concentrations were measured using normalphase liquid chromatography-tandem mass spectrometry (LC-MS/MS). 32 Briefly, 100 lL of serum was loaded onto 96-well Hybrid SPE plates (Sigma-Aldrich, St. Louis, MO, USA) and extracted with 2 9 800 lL acetone. The resulting extract was evaporated and re-suspended in heptane-ethanol (95:5 v/v). Extracts were run on a liquid chromatography-tandem mass spectrometry system (LCMS 8030+; Shimadzu Europa GmbH, Duisburg, Germany), and odd-and even-numbered AR homologues from C17 to C26 were measured using multiple reaction monitoring. Injection-to-injection run time for the method is 3 min. Data are reported as a total AR concentration (sum of all homologues). In some cases, less than 100 lL of serum was available for the mouse serum samples. The exact amount (down to 30 lL for mouse serum) was recorded and quantification corrected for the lower amount of serum. Alkylresorcinols in the mouse chow, and vital gluten samples were analysed by reverse-phase LC-MS/MS using previously published chromatography conditions and the same mass spectrometry conditions as for the serum method. 32 Statistical analyses All data were found to be non-normally distributed (right skewed), so nonparametric tests were used. For the human study, the differences in serum total AR concentrations among 3 groups (treated CD patients, untreated CD patients and healthy controls) were analysed using the Kruskal-Wallis analysis of variance test. The difference between serum total AR concentrations before and after a GFD in CD patients was also assessed by the paired-sample Wilcoxon signed rank test. The statistical significance of the differences in serum total AR concentrations between mice fed a GFD and mice fed a regular mouse chow, was assessed using the MannWhitney rank sum test. When the difference between total AR concentrations in mice before and after feeding a diet with added vital gluten for 8 days was compared, the paired-sample Wilcoxon signed rank test was used. All statistical analyses were performed using a two-sided hypothesis test at the 5% level of significance with SAS version 9.3 (SAS Institute, Inc., Cary, NC, USA). Graphs were drawn in part with GraphPad Prism 6.07 (GraphPad Software, La Jolla, CA, USA).
RESULTS

Total AR concentrations in patients with CD
In the groups included in the study to compare serum levels of total AR between treated and untreated CD patients and normal diet controls, the mean (s.d.) age of untreated CD patients was 40 (13.4) years, and 58% were female, while the mean (s.d.) age of treated CD patients was 42 (11.7), and 56% were female ( (Figure 1 ). There was no significant difference in AR concentrations between patients with untreated CD and controls (P = 0.6). One of the treated (GFD) CD patients had a very high total AR concentration (115.1 nmol/L), likely due to eating quinoa, which is compatible with a gluten-free diet. Recently, we found that quinoa seeds contain AR, though quinoa alkylresorcinols can easily be distinguished from wheat or rye alkylresorcinols by the presence of homologues with even-numbered chain length. 33 Interestingly, the alkylresorcinols concentration of the one treated CD patient who was suspected to have refractory CD had the second highest value of all the treated CD patients (43.3 nmol/L), while one treated CD patient who had the highest alkylresorcinols concentrations is likely to have high concentrations due to eating quinoa, as the even-chained alkylresorcinols homologues C20, C22 and C24, unique to quinoa, were detected in this subject. 33, 34 In addition, we evaluated serum samples of seven additional patients with CD whose samples were available at diagnosis and after following a GFD. The mean (s.d.) age of these patients was 43 (17) years, and the mean (s.d.) duration of GFD was 2.6 (2.0) years. All patients were positive for tTG or endomysial antibodies at diagnosis. After following a GFD, most patients were negative for tTG, except two patients, who were weak positive. Detailed characteristics are shown in Table 2 . These two patients who were weakly positive to tTG did not have intestinal mucosal atrophy and only had increased intraepithelial lymphocytes. Figure 2 compares total AR concentrations in patients with CD before and after following a GFD. The median (IQR) total AR concentrations in serum in patients with CD was 34 nmol/L at diagnosis and significantly decreased to 5.1 (2.5-11) nmol/L after following a GFD (mean duration, 2.1 years) (P = 0.016).
Total AR concentrations in mice fed glutencontaining and gluten-free diets
We evaluated total AR concentrations in different mouse chows. Total alkylresorcinols were found in regular mouse chow (277 lg/g), while only trace amounts were detected in the gluten-free chow (0.3 lg/g). In addition, we found a high level of total alkylresorcinols in glutenfree chow with 5% by weight added gluten (138 lg/g) that was used to evaluate the effect of gluten introduction into a strict GFD on changes of total alkylresorcinols concentration. Figure 3 shows serum concentrations of total alkylresorcinols according to mice fed a regular gluten-containing chow vs. mice fed lifelong with gluten-free chow. As expected, alkylresorcinols concentrations were significantly higher in mice fed a regular gluten-containing chow [median (interquartile range; IQR), 2355 (2157-3353) nmol/L], compared to mice fed lifelong with a gluten-free chow [median (IQR), 1.9 (1.7-2.8) nmol/L] (P < 0.001) (Figure 3) . To evaluate the effect of vital gluten on AR concentrations, we took mice that were weaned and maintained on a gluten-free chow and switched them to the custom-made chow with 5% vital gluten for 8 days. After the mice had been fed the custom-made chow for 8 days, the median (IQR) of their total alkylresorcinols concentrations significantly increased from 1.8 (1.6-2.3) to 16 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) nmol/L (P = 0.008) (Figure 4 ).
DISCUSSION
Following a GFD is currently the only therapy for patients with CD. In addition, as many or more people without CD follow a GFD or avoid gluten-containing products because of perceived discomfort with wheatbased products or concern about the effect of eating gluten on their health. 35, 36 However, useful serum markers to detect gluten intake are essentially absent, and adherence to a GFD often relies on subjective measures such as questionnaires. In the present study, we showed that the total AR concentration in serum could be a good indicator of gluten intake. CD patients on a long-term GFD had significantly lower total AR concentrations as compared to untreated CD patients or healthy controls. Since the CD patients started following a strict GFD, monitored and confirmed by their physician or dietician, this decrease is presumed to be a result of the elimination of gluten-containing foods from the diet. To prove this in a model system, we were able to demonstrate that mice, fed a regular chow that contained whole wheat and wheat germ, had substantially higher AR concentrations than mice fed a lifelong GFD that is by design free of all wheat. Furthermore, when mice fed this gluten-free chow since weaning was switched to a chow containing 5% vital gluten for 8 days, they had a significant increase in alkylresorcinols concentrations before and after vital gluten added chow. This demonstrates that gluten alone can raise serum AR concentrations. Accurate measurement of gluten intake also benefits the population with diagnosed CD. At present, a dietary interview by a skilled dietitian is the gold standard for monitoring adherence to a GFD, 1, 37 but there are several limitations, including difficulty of standardisation, time and cost required and reliance on patients' recall of their diet. Moreover, because gluten is widely used as an ingredient in foods that otherwise would not be expected to contain wheat, dietary recall-based methods may miss important hidden sources of gluten in the diet. In particular, the utilisation of vital gluten, semi-purified wheat gluten, has recently been increased in the baking business and can be found in food products such as additives and meat replacements. In addition, due to the viscoelastic properties of gluten that provide adhesiveness, gluten is even used in medication or beauty products. 2 Serologic markers, including tTG-IgA and anti-gliadin antibodies, have been used to monitor adherence to a GFD, but the change in these markers reflect only longterm gluten contamination in a GFD. [38] [39] [40] In addition, a decrease in serologic markers typically takes several months to appear after the start of a GFD. 39, 40 Such a time interval substantially delays and confounds appropriate treatment, and currently, a lack of declining values after more than 1 year of a GFD is strongly suggestive of gluten contamination. 41 Recently, Comino et al.
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studied the gluten and gliadin 33-mer equivalent peptide epitopes in human faeces to monitor adherence to a GFD. In this study, the 33-mer epitopes were found in the faeces of healthy individuals on a normal gluten-containing diet and of patients with CD on a gluten-containing diet. The 33-mer epitopes disappeared after a GFD was started. However, the gluten peptide excretion in healthy volunteers was variable, suggesting that gluten hydrolysis may also be influenced by other factors, such as the diet, type of gluten-containing food and variability in bacterial degradation. 42 Collecting faecal samples for monitoring gluten excretion is also inconvenient for both the patient and the investigator. 43 Furthermore, Moreno and colleagues 13 also demonstrated that gluten immunogenic peptides were detected in the urine of patients with CD. However, larger studies are needed for the validation of this procedure.
In our study, we found a promising blood-based biomarker for monitoring adherence to a GFD, detected using LC-MS/MS analysis. As alkylresorcinols are measurable in erythrocytes, 44 future analytical methods may be able to measure alkylresorcinols as a biomarker of a GFD on the basis of simple collection of blood spot samples. In addition, the method used requires only simple sample preparation and is suitable for rapid sample throughput (>160 samples per day).
32
A major problem for patients with CD in following a GFD is the contamination of food products that do not obviously contain wheat. Vital gluten is approximately 80% wheat protein (mainly gluten) and is used to improve texture in foods and as a major protein source, especially in vegetarian meat alternatives. Mice fed vital gluten as part of a diet otherwise gluten free had measurably higher concentrations of serum total alkylresorcinols. Although these differences were not major, they indicated that some alkylresorcinols are included with gluten when it is separated from the starch component of wheat flour. This was supported by the finding that vital gluten contained 138 lg/g alkylresorcinols that measured in our study, and alkylresorcinols also found in refined wheat flour (30-50 lg/g). 21 Furthermore, we
showed that alkylresorcinols significantly increased after only 8 days of intake of vital gluten in mice that were strictly maintained with gluten-free chow. These results suggest that alkylresorcinols concentrations could be useful to indication of gluten intake. However, more extensive study is needed to determine the quantity of gluten required to clearly detect alkylresorcinols in serum.
A biomarker that can identify gluten intake will be invaluable for clinicians looking to establish the baseline gluten intake of the patient when testing for CD. Such a biomarker would be especially useful in sero-epidemiological studies to investigate wider effects of gluten on health, as more people are choosing gluten-free diets in the absence of any previously diagnosed gluten associated disease/syndrome. This would be useful in situations where sera have been stored, or where clinical, but no dietary information is available.
A number of studies have demonstrated the strong association between plasma alkylresorcinols and alkylresorcinol intake in a variety of populations, [16] [17] [18] 45 and the overwhelmingly main source of alkylresorcinols in the diet is from the gluten-containing cereals wheat and rye, 23 with minor contributions from barley and quinoa. 34 We have also found that plasma alkylresorcinols are moderately correlated with self-reported gluten intake in an intervention setting. 46 Thus, although there was no measurement of gluten intake in the study population, the alkylresorcinol measurements serve as a good proxy for intake of gluten-containing cereals. In the case of healthy controls measured in this study (Figure 1 ), very low concentrations are just as possible as for people following a gluten-free diet, reflecting that their recent diet has not contained either wheat or rye.
As with all biomarkers, there are limitations with using alkylresorcinols as biomarkers of gluten intake. From the many studies that couple plasma alkylresorcinols with whole grain intake, it is clear that there high inter-individual variability in response to similar doses, and a relatively short half-life of 5 hours for plasma alkylresorcinols. 47 As such, alkylresorcinols are good for detecting recently ingested gluten with a maximum window of detection of 1 week after consuming glutencontaining grains. 22 This means that alkylresorcinol measurements are unlikely to pick up the occasional (accidental) intake of gluten-containing foods in those following a GFD. An advantage of the rapid response of alkylresorcinols to gluten intake is that in contrast to long-term measurements such as tTG-IgA and anti-gliadin antibodies, deviations from a GFD can be detected quickly and resulting changes to diet closely monitored. The high rate of inter-individual variation is also problematic for setting a clear cut-off value for 'eats gluten' and 'does not eat gluten,' mainly from the perspective that very low concentrations may not necessarily mean a GFD. However, finding alkylresorcinols in a blood sample of someone with CD and following a GFD strongly suggest that follow-up with a dietician is required to assist with maintaining a GFD. Furthermore, we have recently found that alkylresorcinols also exist in quinoa grains, 33, 34 which are considered to be a gluten-free grain and is used in gluten-free foods. This could confound the use of alkylresorcinols as biomarkers of gluten intake. However, alkylresorcinols in quinoa include even-numbered alkyl-chain homologues, making it possible to distinguish between alkylresorcinols coming from wheat, rye and barley, or quinoa. In this study, one treated CD patient had a high alkylresorcinol concentration and was found to have high amounts of the even-numbered alkyl-chain homologues, likely reflecting quinoa intake. In an intervention study, we have established decision-tree methodology that allowed the determination of compliance to a gluten-free diet including quinoa, based on both total plasma alkylresorcinols and one of the unique quinoa alkylresorcinol homologues. 34, 46 With further analysis of serum alkylresorcinols in patients with CD and control subjects with well characterised dietary data, it will be possible to implement such decision-tree methodology to aid in the rapid determination of likely variations from a GFD. Future work on establishing serum/plasma alkylresorcinols as biomarkers for adherence to a GFD needs to establish the range of alkylresorcinol concentrations in a larger number of patients on a well-controlled GFD from different populations. This will help to establish cut-off values if possible, as well as identify practical limitations. Quantitative studies to establish the sensitivity of alkylresorcinol to low amounts of wheat or vital gluten intake are also needed.
In conclusion, we have identified a novel potential biomarker for a GFD. While further work is required to fully validate their use, the use of alkylresorcinol concentrations to identify people adhering to a GFD will have important ramifications for confirming how following a GFD affects the management of CD. All authors have read and approved the final version of the manuscript.
